Evolus, Inc. ((EOLS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evolus, Inc. is conducting a non-interventional safety study titled ‘Non-Interventional Post-Authorisation Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines.’ The study aims to evaluate the long-term safety of NUCEIVA in real-world clinical settings, providing crucial insights into its use for treating glabellar lines.
The intervention being tested is prabotulinumtoxinA, a botulinum toxin Type A used to treat moderate-to-severe glabellar lines. The study will observe its safety profile without mandating specific treatment protocols.
This observational study is prospective and multicenter, involving approximately 750 patients across 20 sites in the UK and EU over 18 months. It focuses on collecting safety data from patients receiving up to six treatments of NUCEIVA.
The study commenced on March 15, 2023, with an expected completion by August 4, 2025. These dates are pivotal as they mark the timeline for data collection and analysis, influencing future market strategies.
The study’s progress could influence Evolus, Inc.’s stock performance, as positive safety data may enhance investor confidence and market positioning. Competitors in the aesthetic treatment industry will be closely monitoring these developments.
The study is currently active but not recruiting, with updates available on the ClinicalTrials portal for those seeking further information.